{"disease":{"id":"acute-lymphoblastic-leukemia","name":"Acute Lymphoblastic Leukemia (ALL)","therapeutic_area":"Haematology / Oncology","data":{"aiSummary":"The treatment landscape for ALL is rapidly evolving, with the introduction of new targeted therapies and immunotherapies. Hyper-CVAD and pediatric-inspired regimens remain the standard of care for 1st-line and 2nd-line treatment, respectively. Inotuzumab ozogamicin and blinatumomab have shown promising results in clinical trials and are being explored as potential new treatment options. The use of molecular testing and flow cytometry is becoming increasingly important in the diagnosis and management of ALL, allowing for more personalized treatment approaches.","drug_count":5,"description":"Acute Lymphoblastic Leukemia (ALL) is a type of blood cancer characterized by the rapid proliferation of immature lymphoid cells. The disease is typically treated with chemotherapy, targeted therapy, or a combination of both. Current treatment options include chemotherapy regimens such as hyper-CVAD and pediatric-inspired regimens, as well as targeted therapies like tyrosine kinase inhibitors and monoclonal antibodies.","subtype_count":7},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.902Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"blinatumomab","indication_name":"Pre B-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blincyto","generic_name":"blinatumomab","company_name":"Amgen","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD19","drug_class":"Bispecific CD19-directed CD3-directed T Cell Engager","quality_score":73,"revenue":"1000","mechanism":"Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells."},{"drug_id":"asparaginase","indication_name":"Acute Lymphoblastic Leukemia (ALL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elspar","generic_name":"ASPARAGINASE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":65,"revenue":"600","mechanism":"RYLAZE kills leukemic cells by depleting plasma asparagine, which they need for survival."},{"drug_id":"dasatinib","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sprycel","generic_name":"dasatinib","company_name":"Handa Therap","drug_phase":"marketed","molecular_target":"Ephrin type-B receptor 6","drug_class":"dasatinib","quality_score":74,"revenue":"493","mechanism":"Sprycel works by blocking the activity of a specific protein called Ephrin type-B receptor 6, which is involved in the growth and survival of cancer cells."},{"drug_id":"inotuzumab-ozogamicin","indication_name":"Pre B-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":78,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"inotuzumab","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"inotuzumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD22","drug_class":"CD22-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"200","mechanism":"Inotuzumab ozogamicin is a CD22-directed antibody drug conjugate that targets and kills cancer cells."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":86,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"besponsa","indication_name":"Relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Besponsa","generic_name":"Inotuzumab Ozogamicin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"CD22","drug_class":"Antibody-drug conjugate (ADC)","quality_score":86,"revenue":"200","mechanism":"CD22-directed antibody-drug conjugate delivering cytotoxic calicheamicin to induce DNA breaks and apoptosis."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"calaspargase","indication_name":"Acute Lymphoblastic Leukemia (ALL) in pediatric patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"calaspargase","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"L-asparagine","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"Calaspargase is an L-asparaginase enzyme that catalyzes the conversion of L-asparagine into aspartic acid and ammonia, leading to the depletion of plasma asparagine and the death of leukemic cells."},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"gleevec","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"calaspargase-pegol","indication_name":"Acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Asparlas","generic_name":"CALASPARGASE PEGOL","company_name":"Servier Pharma Llc ","drug_phase":"marketed","molecular_target":"","drug_class":"Asparagine-specific Enzyme [EPC]","quality_score":45,"revenue":null,"mechanism":"Asparlas depletes asparagine, an amino acid that cancer cells rely on for growth."},{"drug_id":"nelarabine","indication_name":"T-cell acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arranon","generic_name":"NELARABINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Arranon works by inhibiting the enzyme responsible for converting nucleosides into their active forms, thereby preventing DNA synthesis in cancer cells."},{"drug_id":"imatinib","indication_name":"Philadelphia chromosome-positive acute lymphoblastic leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"chembl-chembl359744","indication_name":"Acute Lymphoblastic Leukemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"6-tioguanine-standard-maintenance-therapy","indication_name":"Acute lymphoblastic leukemia (ALL) in adult patients who are refractory or resistant to other therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"6-tioguanine+Standard Maintenance Therapy","generic_name":"6-tioguanine-standard-maintenance-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"DNA replication","drug_class":"purine analog","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":32,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07246213","title":"CAYA Cancer Retrospective Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Resonance, Inc.","has_results":false},{"nct_id":"NCT01142427","title":"Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":17463,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01190930","title":"Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9350,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03914625","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03959085","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5951,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02883049","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5949,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00103285","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5377,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT03643276","title":"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Martin Schrappe","has_results":false},{"nct_id":"NCT05639673","title":"Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05929976","title":"InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort","phase":"","overall_status":"RECRUITING","enrollment_count":4900,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT00075725","title":"Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3154,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT00898079","title":"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2545,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02003612","title":"Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2373,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00408005","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1895,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03904134","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1753,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT00026780","title":"Eligibility Screening for a NCI Pediatric Oncology Branch Research Study","phase":"","overall_status":"COMPLETED","enrollment_count":1720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07072585","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1708,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02256137","title":"A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1564,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT05375617","title":"European Prospective Investigation Into Childhood Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Columbia University","has_results":false},{"nct_id":"NCT04187248","title":"The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008","phase":"","overall_status":"COMPLETED","enrollment_count":1248,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT06763302","title":"NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1220,"lead_sponsor_name":"The Children's Hospital of Zhejiang University School of Medicine","has_results":false},{"nct_id":"NCT06860269","title":"A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07297914","title":"Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL","phase":"PHASE2, PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Bambino Gesù Hospital and Research Institute","has_results":false},{"nct_id":"NCT03586401","title":"Creating a Decision Support System for the Corporate Management of Physical Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT04726241","title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":960,"lead_sponsor_name":"PedAL BCU, LLC","has_results":false},{"nct_id":"NCT02112916","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":847,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00897325","title":"Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","phase":"","overall_status":"COMPLETED","enrollment_count":811,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03117751","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":790,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04843514","title":"TDM of Asparaginase in ALL2008","phase":"","overall_status":"COMPLETED","enrollment_count":765,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT00268528","title":"Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission","phase":"","overall_status":"COMPLETED","enrollment_count":720,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02101853","title":"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":669,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00819351","title":"ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":650,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06195735","title":"Forecasting Hypersensitivity Against PEG-asparaginase to Optimize Outcome in ALL","phase":"","overall_status":"COMPLETED","enrollment_count":649,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03123887","title":"Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL","phase":"","overall_status":"COMPLETED","enrollment_count":632,"lead_sponsor_name":"Harbin Hematology and Oncology Institute","has_results":false},{"nct_id":"NCT06392763","title":"Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data","phase":"","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00549848","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT01503632","title":"Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":570,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07223190","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":560,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT00923442","title":"Biology Studies of Hematologic Cancers","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":550,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02847130","title":"Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology","phase":"","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT00897507","title":"DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":520,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02369653","title":"A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":512,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT06785818","title":"Long-term Follow up Local Registry Study of Kymriah in South Korea","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03568266","title":"Pharmacogenomics of Asparaginase Induced Hepatotoxicity","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT02003222","title":"Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":488,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03007147","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":475,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07499349","title":"Establishment of a Phamacokinetik Model for Erwinase Pharmacokinetiks: The Aim of This Sub Study is to Optimize Target Trough Attainment While Minimizing High Exposures That Impose Increased Risk of Side Effects Such as Hyperammonemia","phase":"","overall_status":"RECRUITING","enrollment_count":475,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT04545333","title":"The clonoSEQ® Watch Registry","phase":"","overall_status":"TERMINATED","enrollment_count":465,"lead_sponsor_name":"Adaptive Biotechnologies","has_results":false}],"total":50},"guidelines":[{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of acute lymphoblastic leukemia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of acute myeloblastic leukemia.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of Hodgkin lymphoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of non-Hodgkin lymphoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic breast cancer.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic Wilms' tumor.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic neuroblastoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic soft tissue sarcoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxorubicin-hydrochloride","guideline_body":"FDA label","recommendation":"Doxorubicin Hydrochloride Injection is indicated for the treatment of metastatic bone sarcoma.","line_of_therapy":"any","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}